Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma

Cancer

Volumn 82, Issue 3, 1998, Pages 520-530

  Wagatsuma, Satoshige ^a   Konno, Ryo ^a   Sato, Shinji ^a   Yajima, Akira ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

C Met; Endometrial carcinoma; Hepatocyte growth factor; Tumor angiogenesis

Indexed keywords

ONCOPROTEIN; SCATTER FACTOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTO ONCOGENE; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; SURVIVAL RATE;

EID: 0032005430     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980201)82:3<520::AID-CNCR14>3.0.CO;2-3     Document Type: Article

References (46)

1. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:59-61.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
3. Ausprunk DH, Folkman J. Migration and proliferation of endothelial cells in performed and newly formed blood vessels during tumor angiogenesis. Microvasc Res 1977;14:53-8.
4. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8.
5. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87.
6. Siitonen SM, Haapasalo HK, Rantala IS, Helin HJ, Isola JJ. Comparison of different immunohistochemical methods in the assessment of angiogenesis: lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Mod Pathol 1995;8:745-52.
7. Costello P, McCann A, Carney DN, Dervan PA. Prognostic significance of microvessel density in lymph node negative breast carcinoma. Hum Pathol 1995;26:1181-4.
8. Goulding H, Nik Abdul Rashid NF, Robertson JF, Bell JA, Elston CW, Blarney RW, et al. Assessment of angiogenesis in breast carcinoma: an important factor in prognosis? Hum Pathol 1995; 26:1196-200.
9. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularization to metastasis of non-small cell lung cancer. Lancet 1992;340:145-6.
10. Yamazaki K, Abe S, Takekawa H, Sukoh N, Watanabe N, Ogura S, et al. Tumor angiogenesis in human lung adenocarcinoma. Cancer 1994;74:2245-50.
11. Gasparini G, Weidner N, Malta S, Pazzo F, Boracchi P, Mezzetti M, et al. Intratumoral microvessel density and p53 protein: correlation with metastasis in head and neck squamous cell carcinoma. Int J Cancer 1993;55:739-44.
12. Roychowdhury DF, Tseng A Jr., Fu KK, Weinberg V, Weidner N. New prognostic factors in nasopharyngeal carcinoma: tumor angiogenesis and c-erbB2 expression. Cancer 1996; 77:1419-26.
13. Abulafia O, Triest WE, Sherer DM, Hansen CC, Ghezzi F. Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstet Gynecol 1995;86:479-85.
14. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, et al. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer 1996;69:205-11.
15. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-7.
16. Polverini PJ, Leibovich SJ. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor associated macrophages. Lab Invest 1984;51:635-42.
17. Kandel J, Bossy-Wetzel E, Radvanyi F, Klagsbrum M, Folksman J, Hanahan D. Neovascularization is associated with a switch to the export of BFGF in the multistep development of fibrosarcoma. Cell 1991;66:1095-104.
18. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993;85:241-2.
19. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in-vivo. Nature 1993;362:841-4.
20. Liotta LA, Kleinerman J, Saidel GM. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976;36:889-94.
21. Mandriota SJ, Seghezzi G, Vassalli JD, Ferrara N, Wasi S, Mazzieri R, et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709-16.
22. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol 1992;119:629-41.
23. Grant DS, Kleinman HK, Goldberg ID, Bhargava MM, Nickoloff BJ, Kinsella JL, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993;90:1937-41.
24. Miyazawa K, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, et al. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 1989;163:967-73.
25. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989;342:440-3.
26. Weidner KM, Arakaki N, Vandekereckhove J, Weingart S, Hartmenn G, Rieder H, et al. Evidence for the identity of human scatter factor and human hepatocyte growth factor. Proc Natl Acad Sci USA 1991;88:7001-5.
27. Gherardi E, Gray J, Stocker M, Perryman M, Furlong R. Purification of scatter factor, a fibroblast-derived basic protein which modulates epithelial interactions and movement. Proc Natl Acad Sci U S A 1989;86:5844-8.
28. Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci USA 1986;83:6489-93.
29. Tajima H, Mtsumoto K, Nakamura T. Regulation of cell growth and motility by hepatocyte growth factor and receptor expression in various cell species. Exp Cell Res 1992;202: 423-31.
30. Bottaro DP, Rubin JS, Falleto DL, Chan AML, Kmiecik TE, Vande Woude GF, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
31. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-Met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994;127:1783-7.
32. FIGO news. Int J Gynecol Obstet 1989;28:189-93.
33. Furukawa T, Duguid WP, Kobari M, Matsuno S, Tsao MS. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am J Pathol 1995;147: 889-95.
34. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesions molecule antibodies, as an indicator of node metastases and survival in breast cancer. Lancet 1992;340:1120-4.
35. Parums DV, Cordell JL, Micklem K, Heryet AR, Gatter CK, Mason DY. JC70: a new monoclonal antibody that detects vascular endothelium associated antigen in routinely processed tissue sections. J Clin Pathol 1990;43:752-7.
36. Schlingemann RO, Rietveld FJR, deWaal RMW, Bradley NJ, Skene AI, Davies AJS, et al. Leukocyte antigen CD34 is expressed by a subset of cultured endothelial cells and on endothelial abluminal microprocesses in the tumor stroma. Lab Invest 1990;62:690-6.
37. Fina L, Molgaard HV, Robertson D, Bradley NJ, Monaghan P, Delia D, et al. Expression of the CD34 gene in vascular endothelial cells. Blood 1990;75:2417-26.
38. Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, et al. Overexpression of the MET/HGF receptor in ovarian cancer. Int J Cancer 1994;58:658-62.
39. Natali PG, Prat M, Nicotra MR, Bigotti A, Olivero M, Comoglio PM, et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (Pred Oncol) 1996;69:212-7.
40. Joseph A, Weiss GH, Jin L, Fuchs A, Chowdhury S, O'Shaugnessy P, et al. Expression of scatter factor in human bladder carcinoma. J Natl Cancer Inst 1995;87:372-7.
41. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3.
42. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
43. Rubin JS, Cahn AML, Battaro DP, Burgess WH, Taylor WG, Cech AC, et al. A broad spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci USA 1991;88:415-9.
44. Rosen EM, Goldberg ID, Kacinski BM, Buckholz T, Vinter DM. Smooth muscle releases an epithelial cell scatter factor which binds to heparin. In Vitro Cell Dev Biol 1989;25:163-73.
45. Tsao MS, Zhu H, Giaid A, Viallet J, Nakamura T, Park M. Hepatocyte growth factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ 1993;4:571-9.
46. Wang Y, Selden C, Morgan N, Stamp GWH, Hodgson HJF. Hepatocyte growth factor/scatter factor expression in human mammary epithelium. Am J Pathol 1994;144:675-82.